Skip to main content
Not Found
Live Webinar

Psychopharmacology for Mental Health Professionals


Speakers:
Alan S. Bloom, PhD |  Margaret Bloom, PhD
Duration:
Full Day
Product Code:
LWC045905
Brochure Code:
PWZ90243
Media Type:
Live Webinar - Also available: Digital Seminar | DVD

Dates

     $249.99  $49.99 - Exclusive offer when combined with this live training.
Add On Products

Description

Most clients with DSM-5® diagnoses are being treated with a combination of psychological and pharmacological treatments. Newer drugs are being developed to treat mental disorders based on a better understanding of neurobiological contributions to mental disorders and the latest pharmacological research. To provide appropriate services, you are expected to have a thorough understanding of these common and complex issues. As a mental health professional, keeping up-to-date is essential.

This seminar will update and increase your knowledge of:

  • Neurobiological underpinnings of major DSM-5® diagnoses
  • Effects and side effects of drugs used to treat these diagnoses
  • Responsibilities of the non-prescribing therapist to clients taking psychiatric medication

Specifics of the pharmacological treatment and drugs of choice for Depressive, Bipolar, Schizophrenia Spectrum, Anxiety, OCD, Sleep-Wake, ADHD and Neurocognitive disorders will be presented. Unique to this webcast is information on the common types of psychotherapeutic drugs and other drugs that are abused, and methods for prevention and early detection. Throughout the day, representative case studies will generate discussion and examination of the latest drug treatment for DSM-5® disorders. You will leave this program with knowledge and confidence regarding effective and safe application of pharmacological drugs.

Credits

Planning Committee Disclosure - No relevant relationships

All members of the PESI, Inc. planning committee have provided disclosures of financial relationships with ineligible organizations and any relevant non-financial relationships prior to planning content for this activity. None of the committee members had relevant financial relationships with ineligible companies or other potentially biasing relationships to disclose to learners.  For speaker disclosures, please see the faculty biography.



CE Information Coming Soon

Continuing education credit information is coming soon for this live webcast.
 



Speaker

Alan S. Bloom, PhD's Profile

Alan S. Bloom, PhD Related seminars and products


Alan S. Bloom, PhD, is professor of pharmacology and toxicology at the Medical College of Wisconsin where he teaches psychopharmacology to medical students and neuroscience graduate students. He earned a joint PhD in psychology and pharmacology and consults regularly with psychiatrists and attorneys in drug abuse and other pharmacology related cases.

Dr. Bloom has conducted extensive research on the impact of drugs of abuse (marijuana, cocaine, etc.) on the brain through use of functional magnetic resonance imaging (fMRI). He also directed research on the cognitive effects of chemotherapy drugs administered to women with breast cancer, commonly known as “chemo-brain”. His studies have been funded by the NIH and other national organizations and reported in an extensive number of publications and presentations. Dr. Bloom has served on the NIDA Center grant review panel and is an appointed member of the Controlled Substance Board of the State of Wisconsin.

Dr. Bloom is a strong and experienced presenter providing lively, information-packed seminars. He encourages the active learning of participants through application of the material in case studies and problem-based learning. In 1997 he was elected to membership in the Medical College of Wisconsin Society of Teaching Scholars.

 

Speaker Disclosures:
Financial: Dr. Alan Bloom has an employment relationship with the Medical College of Wisconsin. He receives a speaking honorarium and recording royalties from PESI, Inc. Dr. Alan has no relevant financial relationships with ineligible organizations.
Non-financial: Dr. Alan Bloom is the Vice Chair of the State of Wisconsin Controlled Substances Board. He is a member of the Organization for Human Brain Mapping, the International Brain Research Organization, and the International Society for Magnetic Resonance in Medicine.


Margaret Bloom, PhD's Profile

Margaret Bloom, PhD Related seminars and products


Margaret (Peggy) L. Bloom, PhD, Professor Emerita, Counselor Education and Counseling Psychology, Marquette University, Milwaukee, Wisconsin is a licensed psychologist and NCC certified counselor. Dr. Bloom is nationally recognized for her knowledge and expertise in assessment, DSM diagnosis, and counselor education. She is past chair and member of the board of directors of the Center for Credentialing & Education (NBCC), an elected fellow of the American Psychological Association (APA) and past president of the Association for Counselor Education and Supervision (ACES). Beginning her career as a psychiatric nurse and earning graduate degrees in nursing, counseling and a PhD in counseling psychology, Peggy brings a unique interdisciplinary perspective to each seminar. She has published numerous journal articles and presented professional education seminars across the world on assessment, diagnosis and counselor education.


Speaker Disclosures:
Financial: Dr. Margaret Bloom has an employment relationship with Marquette University and is an assessment mentor for Assessment Academy of the Higher Learning Commission. She receives a speaking honorarium and recording royalties from PESI, Inc. She has no relevant financial relationships with ineligible organizations.
Non-financial: Dr. Margaret Bloom serves as a guest reviewer for The Clinical Supervisor. She is a member of the American Counseling Association, the American Psychological Association, and the Association for Counselor Education and Supervision.


Additional Info

Access Period for Live Webcast

For live CE credit, you must watch the live webcast in its entirety at its scheduled time and complete the CE quiz and evaluation within one week. You will have access for 90 days after the program for review.


Webcast Schedule

Please note: There will be a 70-minute lunch and two 15-minute breaks; one in the morning and one in the afternoon. Lunch and break times will be announced by the speaker and at their discretion. A more detailed schedule is available upon request.


Questions?

Visit our FAQ page at www.pesi.com/faq or contact us at www.pesi.com/info


Objectives

  1. Communicate the neurotransmitter systems and neuroanatomy underlying the biological basis for mental disorders and pharmacotherapy.
  2. Evaluate the role of mental health professionals who treat clients receiving both psychotherapeutic medications and psychotherapy.
  3. Analyze the major classes of drugs used to treat mental disorders and which mental disorders are appropriately treated with each class of drugs.
  4. Analyze the effects and side effects of various psychotropic medications, including antipsychotics, antidepressants, benzodiazepines and anticonvulsants.
  5. Determine the abuse liability of drugs used in the treatment of anxiety, insomnia, pain and ADHD.
  6. Implement methods for prevention and early identification of prescription drug abuse among clients.

Outline

Psychopharmacological Foundations
Core Pharmacological Principles
  • Brain structures & circuits involved in:
    • Emotional regulation
    • Executive function & inhibitory control
    • Reward & pleasure
    • Learning & memory
  • Receptors and neurotransmitters important in the actions of psychopharmacological agents
    • Biogenic amines
    • Excitatory & inhibitory neurotransmitters
    • Endorphins & endocannabinoids
Your role in combined psychological & pharmacological treatments
  • Collaboration & communication with prescribing professionals
  • Managing the combined treatments
    • Referrals for medication
    • Client psycho-education
    • Monitoring drug effects & side effects
    • Promote adherence to combined treatments
Drugs Used in the Treatment of DSM-5® Mental Disorders

Depressive Disorders

  • Neurobiology of depression
  • Drugs used to treat depressive disorders
    • Selective Serotonin Reuptake inhibitors (SSRIs)
      • Effects, side effects and cautions
      • Suicide risk & discontinuation syndrome
      • Serotonin syndrome
  • Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
    • Effects, side effects, and cautions
  • Atypical antidepressant agents
    • Effects, side effects, and cautions
  • Tricyclic antidepressants (TCAs)
    • Effects, side effects, and cautions
    • Why were newer drugs needed?
  • MAO inhibitors
    • Effects, side effects, and cautions
  • Choosing an antidepressant
  • What if first-line antidepressants do not work?
  • Augmentation with antipsychotics
  • What about herbs like St. John’s Wort?
Schizophrenia Spectrum Disorders
  • Biological theories of schizophrenia
  • ”Typical” & “atypical” antipsychotic drugs
    • Effects, side effects & cautions – similarities & differences
  • Latest evidence-based comparisons
  • Drugs for treatment-resistant schizophrenia
  • Other uses of antipsychotic drugs
Bipolar Disorders
  • Biological theories for bipolar disorders
  • Drugs used to treat bipolar disorders
    • A prototype agent – lithium
      • Effects, side effects & cautions
    • Anticonvulsants
      • Effects, side effects & cautions
    • Antipsychotics – approved agents
    • Combination drug therapy
Anxiety, Obsessive-Compulsive & Sleep-Wake Disorders
  • The neurobiology of anxiety-related disorders
  • The structure of sleep
  • Drugs used in the treatment of anxiety & insomnia
    • Benzodiazepines & Benzodiazepine-like drugs
    • Misuse of these drugs in treatment
    • SSRI’s & other drugs used to treat anxiety
Attention-Deficit/Hyperactivity Disorder & Neurocognitive Disorders (Dementia)
  • ADHD
    • Psycho-stimulants
      • Effects, side effects & cautions
    • Alpha-Adrenergic Agonists
  • Major neurocognitive disorders
    • Drugs used in the treatment of cognitive impairment
    • Future treatments
Prescription Drug Abuse
  • Mental disorders & risk of comorbid prescription drug abuse
  • Classes of drugs that are frequently abused
    • Stimulants
    • Sedative-hypnotics
    • Opiates
  • Strategies for the prevention & early identification of prescription drug abuse
Limitations of the Research and Potential Risks

Target Audience

  • Counselors
  • Psychotherapists
  • Psychologists
  • Social Workers
  • Nurse Practitioners
  • Case Managers
  • Marriage & Family Therapists
  • Addiction Counselors
  • Nurses
  • Physicians
  • Clinical Nurse Specialists
  • Pharmacists
  • School Psychologists
  • Occupational Therapists
  • Occupational Therapy Assistants
  • Other Mental Health Professionals

Reviews

5
4
3
2
1

Overall:      4.3

Total Reviews: 12

Comments

Sarah W

"great program. SO informational!"

Jacqueline T

"Super informative course!"

ELISE K

"the whole experience was excellent"

LARA W

"Both the presenter and the quality of the information were fantastic."

Leslie S

"Great seminar, thank you!"

Natalie B

"Excellent course and presentation."

Satisfaction Guarantee
Your satisfaction is our goal and our guarantee. Concerns should be addressed to: PO Box 1000, Eau Claire, WI 54702-1000 or call 1-800-844-8260.

ADA Needs
We would be happy to accommodate your ADA needs; please call our Customer Service Department for more information at 1-800-844-8260.

PESI Mobile App

Access CE trainings on your phone or tablet through our free mobile app. Choose video or audio-only versions of live webcasts and online courses from the world’s best instructors, and complete your CE requirements anywhere, anytime, at your own pace.

https://cdn.pesi23.com/images/android.png     https://cdn.pesi23.com/images/iphone.png

Please wait ...

Back to Top